Background & Objectives
Orphan Drugs (ODs) are medicinal products intended for diagnosis, prevention or treatment of rare diseases. Access to ODs is crucial for patients' health and quality of life. However, patients claim that access to orphan drugs is sometimes restricted, a phenomenon that has grown during the economic crisis. The aim of this study was to identify current problems and future challenges of patients' access to ODs in Greece.
Methods
A qualitative study took place between December 2013 and January 2014. Data were retrieved through policy documents identified through web searches using keywords "orphan drugs" and "rare diseases" in Greek. The selected documents were content analyzed and based on the first results, an interview guide was developed in order to be used in semi-structured interviews with six representatives of key stakeholders in Greece. The interviews were content analyzed and the main problems that the patients with rare diseases face were identified. Furthermore, patients' pathway to access ODs was depicted.
Results
There are two main channels through which the patient can have access to an OD and it is depending on whether it is licensed in Greece or not. In the first case the patient can take the drug through the hospital ( 3. If the monthly cost of the treatment is above 3.000€ , then the hospital board has to approve the request.
The Committee meets and decides
3. The secretary of the Committee receives the request and forwards it to the Committee At the same time IFET performs a market research in order to identify the country where the drug is available at the lowest price.
IFET forwards the request and the patient's record to the National Medicines Organization (EOF) for approval
Conclusions
Ensuring patients' access to ODs in Greece is challenging especially during the economic crisis. Financial constraints and continuous l i l ti h i th h lth t d th h t i l k t tit t i t tb i t ti t ' Th ti l 5. The physician prescribes the drug and the hospital informs the patient p )
6. The patient receives the drug 5. If the decision is positive the patient will be informed and the drug will be ordered If EOF approves the request then IFET orders the drug and delivers it to the hospital pharmacy. Then the doctor prescribes the drug and the patient can arrange his treatment legislative changes in the health system and the pharmaceutical market constitute important barriers to patients' access. The national action plan for rare diseases that was developed in 2008, addresses many of the barriers that our study identified and its implementation can improve patients' access to ODs.
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